We compared the vascular effects of rosiglitazone versus glyburide and evaluated asymmetric dimethylarginine (ADMA) and oxidative stress as potential mechanisms associated with changes in vascular health in patients with type 2 diabetes mellitus (T2DM). Patients were randomized to 6 months of either rosiglitazone (n ϭ 20) or glyburide (n ϭ 16) in addition to metformin. The following variables were measured pre-and post-treatment: glucose, insulin, homeostasis model assessment (HOMA), hemoglobin A1c (HbA1c), C-peptide, blood pressure, lipids, C-reactive protein (CRP), ADMA, 8-isoprostane, oxidized LDL cholesterol, brachial artery flowmediated dilation (FMD), endothelium-independent dilation (EID), and brachial and carotid artery stiffness. Rosiglitazone and glyburide treatment resulted in significant and equivalent decreases in glucose (p Ͻ 0.0001) and HbA1c (p Ͻ 0.0001), with a trend toward decreased HOMA (p ϭ 0.09). Rosiglitazone significantly decreased C-peptide (p Ͻ 0.01) with a strong trend toward decreased fasting insulin (p ϭ 0.05). Rosiglitazone reduced CRP compared with glyburide (p ϭ 0.001), but no differences were observed between groups for ADMA or the markers of oxidative stress. Rosiglitazone significantly improved FMD (p Ͻ 0.05) with trends toward improvements in carotid artery distension (p ϭ 0.099) and distensibility (p ϭ 0.078). In conclusion, compared with glyburide, rosiglitazone improves endothelial function and CRP in patients with T2DM. These improvements are not associated with reductions in ADMA or markers of oxidative stress.
Introduction
The thiazolidinediones (TZDs) have emerged as an effective drug class for glycemic management in patients with type 2 diabetes mellitus (T2DM). Unlike other anti-diabetic medications such as sulfonylureas (promotion of pancreatic insulin secretion), biguanides (reduction of hepatic glucose production), and incretin mimetics (increase in GLP-1), the main mechanism of action of these peroxisome proliferatoractivated receptor gamma (PPAR-␥) agonists is to sensitize the peripheral tissues to the effects of insulin. In addition to residing in the adipose tissue and skeletal muscle (the main sites of insulin sensitization with TZD therapy), PPAR-␥ are also located in macrophages and the vascular wall, 1 where agonists such as TZDs may exert beneficial cardiovascular effects by stimulation of these receptors.
TZDs have been shown to improve blood pressure, [2] [3] [4] components of the lipid profile (mainly pioglitazone), 5 vascular structure and function, 3, [6] [7] [8] [9] [10] [11] coronary artery restenosis, [12] [13] [14] inflammatory and adipokine profile, [15] [16] [17] [18] and atherosclerotic plaque stability. 10, 15, 19, 20 The recent PROactive study reported a non-significant trend (p ϭ 0.095) toward a reduction in all-cause mortality and cardiovascular events/procedures with TZD treatment over 3 years. 21 In this study, there was a significant reduction ( p ϭ 0.027) in the secondary endpoint of all-cause mortality, non-fatal myocardial infarction, and stroke.
Although PPAR-␥ agonists seem to exert their positive effects at least in part by acting directly on the vascular wall, the literature is mixed concerning the effects of the TZDs on endothelial function and potential mechanisms of improvement. Some 3,6,7,11 but not all 23, 24 studies have shown improvements in vasodilating capacity and/or blood flow in coronary and peripheral arteries with TZD therapy. In addition, little is known about the impact on asymmetric dimethylarginine (ADMA) and possible anti-oxidant effects of the TZDs. Although animal data suggest that the TZDs reduce oxidative stress, little data are available in humans. One small, uncontrolled study reported that 12 weeks of pioglitazone therapy significantly increased levels of extracellular superoxide dismutase (EC-SOD), a prominent anti-oxidant found in the vascular wall. 25 Since T2DM is a coronary risk equivalent and is characterized by severe endothelial dysfunction and increased levels of ADMA and oxidative stress, it is important to identify therapies that might provide vascular protection in addition to glycemic control. Therefore, to further define the effects of the TZDs on vascular health and impact on ADMA and oxidative stress, we compared rosiglitazone versus the sulfonylurea glyburide in a head-to-head trial in patients with T2DM. We chose glyburide as the comparator since it is a commonly prescribed sulfonylurea to treat T2DM.
Methods

Patient population
Patients (n ϭ 36) with clinically diagnosed T2DM were randomized to receive 6 months of either rosiglitazone (n ϭ 20) or glyburide (n ϭ 16) in addition to metformin. Patients were recruited from local Minneapolis-St Paul medical clinics and via newspaper advertisements. Verbal and written informed consent was obtained from each individual and the protocol was approved by the Western Institutional Review Board (Olympia, WA, USA). All procedures were conducted in accordance with local institutional and HIPAA guidelines.
Study design
This was a randomized, double-blind, parallel group trial that compared the vascular effects of rosiglitazone versus glyburide in addition to metformin background therapy. Following baseline testing, patients were randomly assigned to one of the two treatment groups for a period of 6 months, after which time re-testing occurred. Concomitant medications known to affect cardiovascular and/or metabolic risk factors were unchanged throughout the study period.
Treatment protocol
Patients currently using TZDs, sulfonylureas, or other anti-diabetic medications underwent a minimum 30-day washout period during which time metformin monotherapy was used to maintain adequate glycemic control. If not already using metformin, patients were placed on this medication (500 mg b.i.d.) for a 2-week run-in period prior to randomization. Rosiglitazone (all patients were up-titrated to 4 mg b.i.d.) and glyburide (maximal dose 10 mg b.i.d.) were up-titrated to achieve goal glycemic control (blood glucose 80-140 mg/dl) throughout the entire 6-month treatment period. If goal blood glucose control could not be achieved with the maximal doses of the respective study medications, then metformin was up-titrated to a maximal dose of 1000 mg b.i.d. Patients monitored their blood glucose levels twice per day during the study and reported the values twice per week to the study nurse and/or physician. Exclusion criteria included current use of insulin, T2DM for greater than 10 years, hemoglobin A1c (HbA1c) Ͻ 6.5% or Ͼ10.5%, and New York Heart Association class III or IV heart failure.
Blood analyses
Fasting blood was assessed for glucose, insulin, HbA1c, C-peptide, lipids, and C-reactive protein (CRP) at the United Hospital Laboratory (Allina Medical System, St Paul, MN, USA). Homeostasis model assessment (HOMA) was used as a marker of insulin resistance and was calculated as (fasting glucose*fasting insulin)/22.5 as described by Matthews et al. 26 Additional blood was processed, flash-frozen, and stored at -80°C for measurement of endothelial and oxidative stress markers: ADMA, 8-isoprostane, and oxidized LDL cholesterol. These plasma biomarkers were measured by enzyme-linked immunosorbent assay (ELISA) at the University of Minnesota Cytokine Reference Laboratory (Minneapolis, MN, USA). All samples were analyzed in duplicate. The coefficients of variation for the plasma biomarkers were as follows: ADMA ϭ 4.0%, 8-isoprostane ϭ 3.6%, and oxidized LDL cholesterol ϭ 3.1%.
Assessment of vascular structure and function
Assessment of brachial and carotid artery structure and function was accomplished following an overnight fast using a standard ultrasound machine (Esaote Biomedica) and an automated wall tracking system (PIE Medical WTS V2, The Netherlands) as previously described in our laboratory. 27, 28 An arterial pressure waveform was obtained using a tonometer placed over the radial artery and calibrated with a standard blood pressure cuff placed on the arm. The resting artery diameter, change in diameter throughout the cardiac cycle (for the determination of distension, compliance, and distensibility), and carotid intimamedia thickness (cIMT) were measured with the patient in a supine position.
Flow-mediated, endothelium-dependent dilation (FMD) was induced by releasing a blood pressure tourniquet around the upper forearm that was inflated for 5 minutes at a pressure of 250 mmHg. The change in diameter was tracked starting at cuff release and for 120 seconds thereafter. FMD was expressed as the percent change from the diameter immediately following cuff deflation to the maximal diameter observed during the 2 minutes following cuff deflation. The reproducibility of this technique in our laboratory has shown a mean difference of 0.42 Ϯ 1.5% for FMD studies separated by 4 months. 29 At least 10 minutes after the measurement of FMD, 0.4 mg sublingual nitroglycerin was administered and the diameter of the brachial artery was measured at 5 minutes post administration. Endothelium-independent dilation (EID) was defined as the percent change from resting baseline diameter to that obtained at 5 minutes post nitroglycerin administration.
Statistical analysis
Data are presented as mean Ϯ standard deviation. Unpaired t-tests were used to compare the glyburide and rosiglitazone groups for baseline variables. To compare the changes in variables between groups before and after the 6-month treatment period, 2 ϫ 2 (group ϫ time) analysis of variance (ANOVA) was used. The ANOVA interaction term was the main a priori-identified analysis of interest. The alpha value was set at 0.05 to indicate statistical significance. GraphPad Prism version 4.0 (San Diego, CA, USA) and SPSS version 8.0 (Chicago, IL, USA) were used for statistical analyses.
Results
Baseline characteristics
A total of five patients (glyburide group ϭ 3 and rosiglitazone group ϭ 2) had documented coronary artery disease and no patients had heart failure. There were no baseline differences between groups for age (rosiglitazone group ϭ 57.9 Ϯ 8.2 years vs glyburide group ϭ 63.1 Ϯ 7.8 years, p ϭ NS) or sex (rosiglitazone group ϭ nine males and 11 females vs glyburide group 10 males and six females, p ϭ NS). There were no between group differences at baseline or over the course of the study for body weight (rosiglitazone group ϭ 96.9 Ϯ 18.0 to 96.4 Ϯ 17.8 kg vs glyburide group ϭ 95.0 Ϯ 18.9 to 97.0 Ϯ 18.5 kg, p ϭ NS). Baseline medications were similar between groups. Approximately 55% of both the rosiglitazone and glyburide groups were taking an angiotensin converting enzyme inhibitor (ACE-I) and/or an angiotensin receptor blocker (ARB), 30% of the rosiglitazone group and 44% of the glyburide group were on a betaadrenergic receptor-blocker (␤-blocker), and 60% of the rosiglitazone group and 81% of the glyburide group were taking statins as background therapy prior to enrollment. Baseline medications remained unchanged throughout the duration of the study.
Clinical variables
All clinical variables are shown in Table 1 . Patients were well matched at baseline for all of the clinical variables except for HDL, which was significantly lower in the glyburide group compared with the rosiglitazone group (p ϭ 0.03). Both rosiglitazone and glyburide added to metformin monotherapy resulted in significant and equivalent decreases in glucose ( p Ͻ 0.0001) and HbA1c ( p Ͻ 0.0001), with a trend toward decreased HOMA ( p ϭ 0.09). Treatment with rosiglitazone resulted in a trend toward decreased fasting insulin levels ( p ϭ 0.05) and a significant decrease in C-peptide ( p Ͻ 0.01) compared with glyburide. There were no differences between groups over time for any of the lipid variables, blood pressure, or heart rate.
Vascular and biochemical variables
Vascular and biochemical data are presented in Table 2 . There were no differences between groups at baseline for any of the vascular variables. Baseline CRP was significantly higher in the rosiglitazone group compared with the glyburide group ( p ϭ 0.03). Compared to glyburide, rosiglitazone treatment resulted in a significant improvement in FMD (p Ͻ 0.05) ( Figure 1 ). No differences were observed between groups for EID. Owing to technical issues, brachial and carotid arterial stiffness measures were only obtained from 19 patients (rosiglitazone group ϭ nine, glyburide group ϭ 10). No differences between groups were observed for brachial artery distension, compliance, or distensibility. However, there was a trend toward significant improvements in carotid artery distensibility (p ϭ 0.08) and distension (p ϭ 0.1) with rosiglitazone versus glyburide therapy. No differences were observed between groups for cIMT. There were no significant differences between groups for any of the endothelial/oxidative stress markers (ADMA, 8-isoprostane, and oxidized LDL). CRP was significantly decreased in the rosiglitazone versus glyburide group ( p ϭ 0.001). To evaluate potential mechanisms associated with improved FMD with rosiglitazone, correlation analyses were performed between changes in FMD and changes in clinical and biochemical variables. No significant associations were found to explain changes in FMD.
Discussion
The main findings of the current study are that in the presence of equivalent improvements in glycemic control, rosiglitazone compared with glyburide significantly improves endothelial function and reduces CRP, with trends toward improvements in carotid artery stiffness in patients with T2DM. However, because no changes were observed for ADMA or the biomarkers of oxidative stress measured in this study, these mechanisms may not be responsible for the improvements in endothelial function. The current findings are in agreement with previous studies that support a pleiotropic role for rosiglitazone in positively modifying many aspects of vascular structure and function in addition to improving glycemic control in patients with T2DM. The literature is somewhat mixed regarding the effects of TZDs on endothelial function and blood flow. Wang et al 3 found that despite a significant increase in LDL cholesterol, patients with the metabolic syndrome receiving rosiglitazone displayed significant improvements in both FMD and in dilation response to nitroglycerin. Similarly, Pistrosch et al 11 reported improvements in insulin sensitivity and forearm blood flow (venous occlusion plethysmography) in a double-blind crossover trial comparing rosiglitazone versus nateglinide in 12 patients with T2DM. In a randomized, double-blind, placebocontrolled study in 80 patients with either hypertension or hypercholesterolemia, Campia et al 6 found that pioglitazone significantly improved endothelial function as measured by forearm blood flow response to bradykinin with concomitant improvements in fasting insulin, HDL cholesterol, triglycerides, free-fatty acids, and CRP. Finally, Esposito et al 7 reported that 1 year of rosiglitazone therapy significantly improved brachial artery FMD and the endothelial function score (L-arginine test) in patients with the metabolic syndrome.
In contrast, two studies have reported that TZDs demonstrate neutral effects on endothelial function. McMahon et al 23 assessed the effects of pioglitazone versus placebo on coronary artery blood flow in patients with T2DM and found no changes with 3 months of treatment. Similarly, Sidhu et al 24 found that compared with placebo, rosiglitazone significantly decreased CRP and vascular adhesion molecules, but failed to improve FMD in 71 male patients with documented coronary artery disease. Data from the current study add to the growing body of literature in this area and are in agreement with previous reports citing improvements in endothelial function. As such, the majority of the studies conducted to date support the contention that TZDs improve endothelial function, suggesting that differences in patient populations studied (patients with coronary artery disease but no T2DM) and small sample sizes utilized (n ϭ 16) may Data are presented as mean Ϯ standard deviation. P-value denotes ANOVA interaction term. explain the lack of significant findings in the studies by McMahon et al 23 and Sidhu et al 24 respectively.
We measured ADMA in this study as a marker of endothelial activation and impaired nitric oxide (NO) bioavailability. ADMA is an endogenous inhibitor of NO and is likely a cause and/or consequence of vascular oxidative stress. 30 One small (n ϭ 7), uncontrolled trial showed that 12 weeks of rosiglitazone therapy significantly decreased levels of ADMA in patients with insulin resistance. 31 More recently, Wang et al 32 reported that 8 weeks of rosiglitazone therapy (4 mg q.d.) versus placebo significantly reduced ADMA levels in patients with the metabolic syndrome. Furthermore, reductions in ADMA correlated with improvements in brachial artery FMD suggesting that changes in this endothelial marker might be a potential mechanism for the observed improvements in vascular function with TZD therapy. In contrast to these findings, we did not observe an improvement in ADMA in the current study. However, our sample was smaller and was comprised of patients with T2DM, who may respond differently to TZD therapy compared to patients with the metabolic syndrome. In addition, prior to randomization, all of the patients in the current study were taking metformin, which has been shown to reduce levels of ADMA. 33 Therefore, concomitant metformin therapy may have overshadowed the potential beneficial effects of rosiglitazone on ADMA.
We measured two different plasma markers of oxidative stress to evaluate the potential systemic antioxidant effects of rosiglitazone and to determine whether reductions in oxidative stress with this therapy might be a mechanism for improved endothelial function in patients with T2DM. 8-Isoprostane, a measure of oxidized arachidonic acid, is a reflection of systemic oxidative stress 34 and is an independent risk marker for coronary heart disease. 35 Oxidized LDL cholesterol is fundamentally involved in the atherosclerotic process and serves as a marker of both systemic and vascular oxidative stress. We were unable to show any improvement in oxidative stress with rosiglitazone therapy in the current study, indicating that this may not be a prominent mechanism whereby rosiglitazone improves endothelial function in patients with T2DM. However, these findings should be interpreted in light of the fact that more than two-thirds (69%) of the patients in our study were taking statins and over half (56%) were taking either an ACE-inhibitor or angiotensin receptor blocker. These medications have been shown to have anti-oxidant effects and may have masked any potential reductions in reactive oxygen species with rosiglitazone therapy. Alternatively, the anti-oxidant activity of rosiglitazone may be predominately intracellular 36 and may not be detectable with the systemic markers of oxidative stress used in the current study.
In the current study, it is unclear what mechanism(s) was/were responsible for the observed improvement in endothelial function. This improvement is probably not related to glycemic control since both groups experienced similar decreases in fasting glucose, HbA1c, and HOMA, and changes in these variables were not associated with changes in endothelial function. The significant reduction in CRP with rosiglitazone therapy might be partially responsible for the improved endothelial function. However, no correlations were found between changes in CRP and improvements in FMD either within the rosiglitazone group alone, or in the study sample as a whole. The most plausible explanation is that rosiglitazone improves endothelial function through a mechanism not measured in the current study. For example, previous studies have shown that the TZDs improve adipokine levels such as adiponectin and resistin, 16, 18 which may stimulate improvements in endothelial function. Lastly, it is possible that rosiglitazone, via PPAR-␥, acts directly on the vasculature to increase NO bioavailability and improve endothelial function. In support of this hypothesis, Hetzel et al 22 recently reported that short-term treatment (21 days) with rosiglitazone significantly improved FMD in 10 healthy, non-obese individuals within 1 day of the initiation of therapy, well before any indirect mechanism could have stimulated improvement.
It should be noted that two studies have recently been published regarding the effects of rosiglitazone therapy on cardiovascular outcomes. 37, 38 The first was a meta-analysis of 42 trials in which rosiglitazone therapy was utilized in patients with T2DM. 38 Results suggested that rosiglitazone may increase the risk for myocardial infarction and death from cardiovascular causes. However, an interim analysis of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycemia in Diabetes (RECORD) trial, a prospective study of rosiglitazone on cardiovascular events, showed no increase in the occurrence of myocardial infarction or incidence of death from cardiovascular causes. Although only an interim analysis, these data suggest that rosiglitazone is not associated with an increase in cardiovascular events. More definitive conclusions can be drawn once the full results of this trial are available.
A few limitations of the current study should be mentioned. First, a larger sample size may have increased the statistical power to detect small changes in ADMA, 8-isoprostane, and oxidized LDL cholesterol. Second, although not statistically different, the sex composition between groups was not matched, possibly impacting our results. Finally, we used ELISA to measure ADMA and markers of oxidative stress in the blood. High performance liquid chromatography (HPLC) is considered a more sensitive and accurate method compared to ELISA, especially for the measurement of ADMA.
In conclusion, the main findings of the current study are that compared to glyburide, rosiglitazone significantly improves endothelial function and reduces CRP, but has no effect on ADMA or markers of oxidative stress in patients with T2DM. These results suggest that rosiglitazone does not have anti-oxidant properties and that improvements in endothelial function are mediated via other mechanisms or through direct effects on the vascular wall. The current data add to the growing body of literature suggesting that TZDs positively modify many aspects of vascular structure and function and provide a greater understanding of the potential mechanisms of improvement.
